Klaus Giese

5.6k total citations · 2 hit papers
38 papers, 4.5k citations indexed

About

Klaus Giese is a scholar working on Molecular Biology, Cancer Research and Genetics. According to data from OpenAlex, Klaus Giese has authored 38 papers receiving a total of 4.5k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Molecular Biology, 6 papers in Cancer Research and 5 papers in Genetics. Recurrent topics in Klaus Giese's work include RNA and protein synthesis mechanisms (7 papers), Genomics and Chromatin Dynamics (7 papers) and RNA Interference and Gene Delivery (6 papers). Klaus Giese is often cited by papers focused on RNA and protein synthesis mechanisms (7 papers), Genomics and Chromatin Dynamics (7 papers) and RNA Interference and Gene Delivery (6 papers). Klaus Giese collaborates with scholars based in Germany and United States. Klaus Giese's co-authors include Rudolf Grosschedl, John M. Pagel, Jeffery S. Cox, Jörg Kaufmann, Chris Kingsley, Jessica R. Kirshner, Ansgar Santel, Anke Klippel, Xiang Li and John J. Love and has published in prestigious journals such as Nature, Cell and Proceedings of the National Academy of Sciences.

In The Last Decade

Klaus Giese

38 papers receiving 4.3k citations

Hit Papers

HMG domain proteins: architectural elements in the assemb... 1992 2026 2003 2014 1994 1992 200 400 600

Peers

Klaus Giese
Duhee Bang South Korea
Lawrence Lum United States
Albert J. Courey United States
S Y Ng United States
Pedro Aza‐Blanc United States
Steven R. Schwarze United States
Rachel E. Rempel United States
Klaus Giese
Citations per year, relative to Klaus Giese Klaus Giese (= 1×) peers Tatsuo Takeya

Countries citing papers authored by Klaus Giese

Since Specialization
Citations

This map shows the geographic impact of Klaus Giese's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Klaus Giese with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Klaus Giese more than expected).

Fields of papers citing papers by Klaus Giese

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Klaus Giese. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Klaus Giese. The network helps show where Klaus Giese may publish in the future.

Co-authorship network of co-authors of Klaus Giese

This figure shows the co-authorship network connecting the top 25 collaborators of Klaus Giese. A scholar is included among the top collaborators of Klaus Giese based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Klaus Giese. Klaus Giese is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Radloff, Katrin, Birgitt Gutbier, Hanieh Moradian, et al.. (2023). Cationic LNP-formulated mRNA expressing Tie2-agonist in the lung endothelium prevents pulmonary vascular leakage. Molecular Therapy — Nucleic Acids. 34. 102068–102068. 8 indexed citations
2.
Strumberg, Dirk, Beate Schultheis, Ansgar Santel, et al.. (2013). Antimetastatic Activity of Atu027, a Liposomal Sirna Formulation, Targeting Protein Kinase N3: Final Results of a Phase I Study. Annals of Oncology. 24. i7–i7. 3 indexed citations
3.
Strumberg, Dirk, Beate Schultheis, W. Meyer‐Sabellek, et al.. (2012). Antimetastatic activity of Atu027, a liposomal small interfering RNA formulation, targeting protein kinase N3 (PKN3): Final results of a phase I study in patients with advanced solid tumors.. Journal of Clinical Oncology. 30(15_suppl). e13597–e13597. 4 indexed citations
4.
Strumberg, Dirk, Beate Schultheis, Christiane Vank, et al.. (2011). Phase I clinical development of Atu027, a siRNA formulation targeting PKN3 in patients with advanced solid tumors. International Journal of Clinical Pharmacology and Therapeutics. 50(1). 76–78. 112 indexed citations
5.
Santel, Ansgar, Manuela Aleku, Nadine Röder, et al.. (2010). Atu027 Prevents Pulmonary Metastasis in Experimental and Spontaneous Mouse Metastasis Models. Clinical Cancer Research. 16(22). 5469–5480. 81 indexed citations
6.
Schwarzer, Rolf, Daniel Tondera, W. Arnold, et al.. (2004). REDD1 integrates hypoxia-mediated survival signaling downstream of phosphatidylinositol 3-kinase. Oncogene. 24(7). 1138–1149. 111 indexed citations
7.
Tondera, Daniel, Ansgar Santel, Rolf Schwarzer, et al.. (2004). Knockdown of MTP18, a Novel Phosphatidylinositol 3-Kinase-dependent Protein, Affects Mitochondrial Morphology and Induces Apoptosis. Journal of Biological Chemistry. 279(30). 31544–31555. 123 indexed citations
8.
Leenders, Frauke, Kristin Möpert, Ansgar Santel, et al.. (2004). PKN3 is required for malignant prostate cell growth downstream of activated PI 3‐kinase. The EMBO Journal. 23(16). 3303–3313. 81 indexed citations
9.
Giese, Klaus, Jörg Kaufmann, Gijsbertus J. Pronk, & Anke Klippel. (2002). Unravelling novel intracellular pathways in cell-based assays. Drug Discovery Today. 7(3). 179–186. 24 indexed citations
10.
Gebhardt, Frank, Frauke Leenders, Frank Czauderna, et al.. (2002). GeneBlocs Are Powerful Tools to Study and Delineate Signal Transduction Processes That Regulate Cell Growth and Transformation. Antisense and Nucleic Acid Drug Development. 12(3). 131–143. 27 indexed citations
11.
Krappmann, Daniel, Eunice N. Hatada, Jun Li, et al.. (2000). The IκB Kinase (IKK) Complex Is Tripartite and Contains IKKγ but Not IKAP as a Regular Component. Journal of Biological Chemistry. 275(38). 29779–29787. 97 indexed citations
12.
Hong, Xin, James C. Stephans, Greg Harrowe, et al.. (2000). Identification of a novel aspartic-like protease differentially expressed in human breast cancer cell lines11GenBank accession number: BankIt246393 AF117892.. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease. 1501(2-3). 125–137. 17 indexed citations
13.
Giese, Klaus, John M. Pagel, & Rudolf Grosschedl. (1997). Functional analysis of DNA bending and unwinding by the high mobility group domain of LEF-1. Proceedings of the National Academy of Sciences. 94(24). 12845–12850. 53 indexed citations
14.
Stephans, James C., et al.. (1996). Positive selection system to screen for inhibitors of human immunodeficiency virus-1 transcription. Nature Biotechnology. 14(11). 1592–1596. 8 indexed citations
15.
Love, John J., Xiang Li, David A. Case, et al.. (1995). Structural basis for DNA bending by the architectural transcription factor LEF-1. Nature. 376(6543). 791–795. 495 indexed citations
16.
Grosschedl, Rudolf, Klaus Giese, & John M. Pagel. (1994). HMG domain proteins: architectural elements in the assembly of nucleoprotein structures. Trends in Genetics. 10(3). 94–100. 695 indexed citations breakdown →
17.
Giese, Klaus, Jeffery S. Cox, & Rudolf Grosschedl. (1992). The HMG domain of lymphoid enhancer factor 1 bends DNA and facilitates assembly of functional nucleoprotein structures. Cell. 69(1). 185–195. 598 indexed citations breakdown →
18.
Giese, Klaus & Alap R. Subramanian. (1991). Expression and functional assembly into bacterial ribosomes of a nuclear‐encoded chloroplast ribosomal protein with a long NH2‐terminal extension. FEBS Letters. 288(1-2). 72–76. 10 indexed citations
19.
Kavousi, Maryam, et al.. (1990). Nucleotide sequence and map positions of the duplicated gene for maize (Zea mays) chloroplast ribosomal protein L2. Nucleic Acids Research. 18(14). 4244–4244. 8 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026